Presentation Current WHO guidance, strategies and lessons learnt of pre- and post-validation surveillance of NTDs
El pilar 3 de la Estrategia técnica mundial contra el paludismo 2016-2030 insta a transformar la vigilancia del paludismo en una intervención básica en todos los países donde el paludismo es endémico, así como en los países que han eliminado el paludismo pero siguen siendo susceptibles de que... se restablezca la transmisión. Este manual de referencia abarca temas relevantes para ambos contextos.
Los destinatarios de este manual son el personal que trabaja en los ministerios de salud, los programas nacionales contra el paludismo y los sistemas de información sanitaria; los asociados que participan en la vigilancia del paludismo; y los funcionarios técnicos de la OMS que asesoran a los países sobre la vigilancia del paludismo.
more
The WHO Mekong Malaria Elimination (MME) programme hosted a 3-day meeting on 15–17 November 2023 in Siem Riep, Cambodia for representatives from national malaria programmes, research institutions, partners, donors, WHO and UN agencies. The meeting provided a forum to discuss surveillance systems, ...the future priorities for the WHO Malaria Elimination Database and areas of improvement for data sharing, the efficacy of antimalarial drugs, progress made in malaria elimination, and challenges raised by P. vivax elimination.
more
This practical document is available to support programmes and partners to design and implement risk communication strategies to achieve high uptake of malaria vaccination.
A VaccinesWork guide: news, science explainers and reported dispatches giving you everything you need to know about the world’s first malaria vaccine and its historic roll-out.
The following appendices of the Guide for introducing a malaria vaccine containing key messages are available for country adaptation
Clinical Pharmacology: Advances and Applications, 2025:17 29–47
Preferred product characteristics and clinical development considerations
Tropical Medicine and Health (2023) 51:29
Two malaria vaccines are currently WHO prequalified and recommended1 for use to prevent
P. falciparum malaria in young children, the RTS,S/AS01 vaccine, currently manufactured by
GlaxoSmithKline (GSK), and the R21/Matrix-M vaccine, manufactured by Serum Institute of India
Pvt (SII)
Lancet Microbe 2024; 5: e519
Presentation OPT-SMC malaria vaccine workshop - Jan 2023
WHO position paper on malaria vaccines, Weekly Epidemiological Record 10 May 2024
Brief Introduction Malaria Vaccine Training. For countries planning malaria vaccine introduction, WHO has developed training packages of slide sets on key topics for health workers in English and French that can be downloaded and customized to meet specific country needs:
Programa de Implementação da Vacina contra a Malária: 2019 – 2023.
This paper is the first quantitative analysis of how the impact of extreme weather events, such as floods and cyclones, affects the malaria burden on the continent, as well as the implications of long-onset climate change. This research involved developing a climate model to predict changes in inten...sity, duration, and frequency of floods and cyclones across the continent
more